Aphria (APHA) is among the biggest producers in the cannabis sector. From a valuation standpoint, Aphria has been trading at a discount compared to Canopy Growth (WEED) and Aurora Cannabis (ACB). The company’s corporate governance has concerned investors. Aphria is addressing the issue. Investors are working to increase their confidence in Aphria.
Currently, 12 analysts are covering Aphria stock—one more compared to the previous month. Among the 12 analysts, three recommended a “strong buy,” while six recommended a “buy” on the stock. The consensus recommendation for Aphria is a “buy.” The consensus recommendation didn’t change from the previous month.
Two analysts recommended a “hold” for Aphria, while one analyst recommended a “sell” in May.
The consensus target price for Aphria is slightly lower at 16.6 Canadian dollars in May—compared to 16.8 Canadian dollars in April. Aphria closed at 9.4 Canadian dollars on May 29, which left an upside potential of 78%.
Canopy Growth (WEED) has a “buy” rating in May with a target price of 76.2 Canadian dollars. Tilray (TLRY) has a “hold” rating with a target price of $94.9. Cronos Group (CRON) has a “sell” rating with a target price of 19.6 Canadian dollars.